Nodules in the thyroid: what actually needs to happen now

You are sitting in the car reading the slip of paper again. There is a word on it you never needed before. Nodule. Next to it a number in millimetres and an abbreviation that means nothing to you.

The ultrasound was really about something else. A bit of fatigue, a routine lab test, a stiff neck. The appointment with the specialist is three weeks away, and until then there is the internet.

Many people know this moment. In my consultations I hear the same half sentence almost every week: could this be cancer.

So I do not begin with reassurance. I begin with numbers. Numbers carry further.

You are not the exception, you are the rule

The first question almost everyone asks is: why me?

The honest answer: not only you. Rather about every second adult around you, depending on how closely one looks. Germany has one of the largest investigations in the world on this.

And those 33 percent are not a constant of nature. They are a property of the equipment.

The new German S3 guideline on thyroid nodules, published in March 2026, works with 41 percent of adults carrying nodules. That is around 28.7 million people. And it estimates that about 80 percent of all nodules are never discovered.

And now to the number you are actually here for.

So where do the higher figures come from that are everywhere? From specialised centres, which report 7 to 15 percent. People do not end up there by chance, but because something looked suspicious beforehand. That is selection and not biology.

The German guideline turns this into a ratio that is rarely written out: for roughly every 100 thyroid nodules there is one malignancy that very probably takes a harmless course. For roughly 41,000 nodules there is one malignancy with a fatal course.

Why it affects women more often, and why age counts

The population study SHIP broke this down across the lifespan. In women between 25 and 34 years, nodule frequency was 17.4 percent, and between 75 and 88 years it was 72.3 percent. In men of the same age groups it was 12.5 and 51.7 percent.

Nodules are therefore less a disease than a form this organ takes as it ages, modulated by hormones and iodine supply. Why oestrogen and thyroid tissue are so closely connected is described in Thyroid and female hormones.

Goiter, nodule, nodular goiter

Three words, three different things. Goiter means the whole organ is enlarged, above 18 millilitres in women and above 25 in men. Nodules are circumscribed areas that differ from the rest. Both together is called nodular goiter.

And now a sentence I appreciate in the new guideline. It notes itself that these volume limits were set on non representative samples and without reference to symptoms. A guideline that qualifies its own cut-offs earns trust.

By the way, only 5 to 24.9 percent of the nodules found on ultrasound can be felt at all. If your doctor felt nothing and the ultrasound still shows something, that is the normal case.

And now you know why the first sensible question is not what to do about the nodule.

Why Germany is a country full of nodules

There is a map of these findings, and it does not follow a random distribution. In the north east the rate of abnormal ultrasound findings is lower than in the south, and at the same time there are more people there with a suppressed TSH. Both have to do with a single element.

The mechanism behind it is simple, and it explains almost everything that follows.

Where does Germany stand today? No longer in classic deficiency territory, but not comfortably supplied either.

Seen through the lens of functional medicine this is an uncomfortable punchline. Cause instead of symptom explicitly does not mean treating the nodule here. It means asking why an entire country is full of nodules. The answer lies decades back and concerns the population, not your supplement shelf.

From the KPNI perspective a second layer is added. There is no symptom for successful compensation. The body does not report success, it only reports failure. That is why such a finding always comes as a surprise.

How much iodine makes sense and when it becomes too much is described in Putting iodine in perspective. Here iodine remains the explanation for the frequency, not the treatment.

And now you know why the map of your region says more about your finding than your last year did.

What is written in your report, and what size does not mean

Pick up the slip of paper again. It probably contains words like hypoechoic, smoothly demarcated, echogenic foci, and somewhere a category with a number.

These words are not jargon designed to intimidate. They are a checklist, and you can read it. Because the cancer risk does not sit in the size of the nodule. It sits in six features that an ultrasound probe can make visible.

Now the part that easily gets lost when reading a report. Individually these features are surprisingly weak.

The German S3 guideline puts the sensitivity of the single criteria microcalcification, irregular margin and shape at 30 to 60 percent, and the specificity of solidity and hypoechogenicity at about 50 percent. So a single feature decides nothing at all. Only from two abnormal criteria onward does the information value rise.

TIRADS, EU-TIRADS, ACR TI-RADS: what these categories mean

Because single signs are so weak, they were combined into systems. They all have similar names, and that causes confusion.

The EU-TIRADS of the European Thyroid Association is widespread in Germany and Austria. It defines an ultrasound lexicon, a standardised report and four risk classes with linked biopsy recommendations. One stated aim is for two examiners to arrive at the same result.

The ACR TI-RADS is the point system from the reading aid above, arithmetically the strictest and therefore the one that saves the most biopsies. The ATA patterns instead work with five described images, each assigned a risk and a size threshold.

If your report says TIRADS 3, many forums will tell you that is already suspicious. In fact what is written there is a risk that the guideline puts at 1.7 to 10 percent, and which it explicitly places lower still for general practice. And the systems are not interchangeable.

And one more caveat, which the European guideline itself names as the main drawback: ultrasound is only as good as the hand guiding it. In a Roman comparison of 107 nodules, specificity was 88.75 percent for the experienced radiologist and significantly lower at 76.25 percent for a trained student. With an unclear finding, a second opinion from someone with a thyroid focus is therefore a factual option and not an insult.

For distinction: uniformly hypoechoic, restless tissue without a circumscribed nodule is something else. That is often the picture of autoimmune thyroiditis, and it is covered in Hashimoto and the causes in the immune system.

Myth one: size

Almost everyone reads the millimetre figure first and assumes that bigger means more dangerous. This assumption has been studied well, and it does not hold.

Myth two: growth

The second reflex is the follow-up appointment in six months. The data on this are clear as well.

The German S3 guideline has turned this into an unusually clear statement: nodule growth is not suitable as a feature for distinguishing between malignant and benign thyroid nodules.

And now you know why the number you looked at first is the least informative one on the whole slip of paper.

Hot, cold, or not scanned at all

A question I often hear: why did they not take blood before the ultrasound. Or the other way round: why are they sending me to nuclear medicine now.

The workup has an order, and each step decides whether the next one is needed.

Why does TSH come so early? Because a single value reorganises all the logic that follows. A low TSH means that hormone is being produced somewhere without the pituitary having asked for it. With a nodule that usually means: this area is working on its own. On scintigraphy it lights up, because it takes up more labelled iodine than the rest. That is the hot nodule.

And the consequence that many people do not know: with a hyperfunctioning nodule, the German S3 guideline says that as a rule no further workup for malignancy should be done. The reason has to do with the growth stimulus from section two.

How common is such autonomy? More common than most people think. In the SHIP cohort, 11 percent had a TSH below 0.3, rising from about 5 percent among 20 to 29 year olds to about 20 percent among 70 to 79 year olds.

And the cold nodule? It takes up little or no iodine. That can be a cyst, a scarred area, an inflamed segment or a benign overgrowth. Only a small part is malignant. Cold means: ultrasound decides what comes next, not scintigraphy.

The treatment of hyperthyroidism itself does not belong here. How autonomy and Graves disease differ, which paths exist and where the limits lie is described in Graves disease and hyperthyroidism. Which blood values make sense when, and which you can spare yourself, is described in Thyroid blood values: which ones really count.

And now you know why a single laboratory value decides what the rest of the path looks like.

The biopsy, and when it is really needed

The word biopsy sounds like a procedure. Like an operating theatre, anaesthesia, aftercare. Many people tell me they postponed the appointment out of fear of it.

The reality is less spectacular. A very thin needle, thinner than for a blood draw, guided into the nodule under ultrasound, a few seconds, usually without anaesthesia. A plaster afterwards.

The German review in Deutsches Ärzteblatt describes it as an inexpensive, technically simple procedure with little burden that prevents unnecessary operations. The S3 guideline puts the side effects at 8.9 percent pain and 0.3 to 2.3 percent bleeding. For comparison: with thyroid surgery, the rate of permanent vocal cord nerve palsy is 1.5 percent.

When a biopsy is done

Not by size alone. The threshold arises from risk level and diameter together, as in the table above. The more suspicious a nodule looks, the smaller it may be to justify a biopsy. And conversely, a purely cystic or spongiform nodule usually needs none at all, even when it is large.

What Bethesda means

The result comes back in one of six categories, named after the location of an American consensus conference. The third edition dates from 2023.

The uncomfortable part sits in categories III and IV. About 20 to 30 percent of all biopsies land there.

And because molecular tests are currently being traded as the big solution, here is the damper right away.

Calcitonin: where guideline and study diverge

And now you know why the order ultrasound before needle and needle before scalpel is not bureaucracy but protection.

How often to check, and when to stop

There is an appointment that many people carry around with them for years. The check-up. Once a year, sometimes every six months, always with the same quiet unease two weeks beforehand.

In my clinical experience this appointment often serves habit more than safety. That is an observation, not a study result. The studies do exist, however, and they are remarkably relaxed.

The last point is remarkable. A German S3 guideline writes that stopping should be discussed. That is not a lapse in diligence but the consequence of three good data sets.

The timing pattern from the large German care cohort fits this: 155 of the 189 carcinomas in the first year, 25 in years two to five, 9 in years six to ten, and beyond ten years none at all. After five years of follow-up the rate fell below one case per thousand. In that range, an annual examination is likely to generate more new incidental findings than open questions it answers.

For distinction: if you have complaints despite unremarkable values, that is a topic of its own and usually has nothing to do with the nodule. On that there is Normal values, symptoms all the same and Functional hypothyroidism.

And now you know why the sentence about stopping can stand in a guideline without being negligent.

The overdiagnosis question, calculated honestly

Now a section that rarely appears in patient guides. It challenges an intuition that sits deep: the earlier you find something, the better. For some cancers that is correct. With the thyroid it is more complicated, and the reason begins in the autopsy room.

If a third of the population carries microscopic foci, then the intensity of searching decides how many diagnoses arise. That is exactly what can be observed across a whole country.

South Korea is regarded as an extreme case, because thyroid ultrasound was offered there for years as a cheap add-on service. The objection that this has nothing to do with Europe does not hold, however.

The German S3 guideline works the whole cascade through. Two groups of 100,000 adults each, one with ultrasound screening, one without, over ten years.

Read the first and the last row together. The same number of people die of thyroid cancer. Three additional people die from the treatment of a cancer that would never have killed them.

That is why the guideline contains a sentence that is only slowly becoming known because of its novelty: ultrasound and palpation should not be used as screening for thyroid nodules, not even in risk groups. And it lists a category of harm that is rarely named: psychological stress and sleep disturbance caused by the suspected diagnosis.

Through the KPNI lens this is consistent. A suspicion of cancer is a stimulus for the nervous system that can alter cortisol rhythm, sleep and immune status over weeks. Anyone who creates that stimulus without benefit has not done nothing.

Finally a number that alarms people when read without context.

And now you know why a guideline in Germany can advise against searching without underestimating the seriousness of the matter.

What lifestyle can contribute, and what it cannot

Here it gets uncomfortable, and specifically for my own side.

The most common question on this topic is: can I get rid of the nodule again. With iodine, with selenium, with a change of diet, with anything. The German S3 guideline answers it in three sentences, and it answers with no.

Clinical tradition without a strong study base: the combination of levothyroxine and iodine was prescribed in Germany for decades in nodular goiter, long before there were solid endpoint data on it. That tradition is the reason why the guideline's refusal surprises so many people.

This is a clear statement against part of what integratively working practices offer. I could push it into a footnote, and I consider that wrong. Because the guideline has good reasons, and the most interesting part of it is this: it bases its refusal on a German trial that did show an effect.

Added to this is the price side from a Cochrane review.

What still makes sense

If the nodule itself is not a point of attack, that does not mean there is nothing to do. The point of attack lies elsewhere, in three places for which there are numbers.

First, iodine supply. An adequate iodine supply at population level prevents the development of goiter. What is not established is that iodine shrinks an existing nodule. The guideline searched systematically and could not derive an evidence based recommendation for the primary prevention of nodules; for goiter only a consensus statement exists. That is a population topic, not a treatment plan for your finding. Details in Putting iodine in perspective.

Second, smoking. This figure rarely appears in thyroid guides.

Third, metabolism. Here it gets interesting and stays cautious at the same time.

Mechanistically plausible, human studies thin: insulin and insulin like growth factors stimulate thyroid cells in the laboratory, and a persistently raised insulin level could therefore be an additional growth stimulus alongside TSH. This pathway is not established in humans.

And selenium, honestly

Selenium appears in functional medicine with almost every thyroid topic. For nodules it holds that there are associations, no causality, and signals pointing in both directions.

A large review from Odense and Surrey describes a low selenium status as epidemiologically linked with autoimmune thyroiditis, Graves disease and goiter. The same work emphasises that health harms occur at both ends of the intake range, and states itself that the broad use goes beyond what the recommendations support.

The German S3 guideline formulates a statement on this with evidence level 1: a causal link between selenium and nodules, carcinomas or goiter is not established, and no recommendation for supplementation is made. Some investigations even show a raised risk with higher selenium values.

More on this in Selenium, zinc, iron and vitamin D, in Nutrition in Hashimoto and in Iron deficiency, thyroid and sleep.

And now you know why an integratively working physician offers less at this point rather than more.

When it really is urgent, and what happens then

Everything written so far applies to the quiet case: the incidental finding without complaints, without an abnormal palpation finding, without a relevant history. There is the other case. It is rare, and that makes recognising it all the more important.

And if something really does have to be treated?

Surgery

It is the established path with a confirmed or highly suspicious finding, with mechanical obstruction and with very large goiters. Its complication rates are listed in the German guideline and belong in every consent discussion: permanent vocal cord nerve palsy in 1.5 percent, need for speech therapy in 4.5 percent, readmission for calcium deficiency in 4.1 percent, postoperative bleeding in 1.7 percent, death in 0.2 percent. These figures are not an argument against a necessary operation. They are the argument for not doing an unnecessary one.

Radioiodine with autonomy

With a hot nodule of functional relevance, radioiodine therapy is established. It uses exactly the property that makes the nodule hot: it takes up iodine especially greedily and therefore receives the main dose, while the throttled remaining tissue is largely spared. Whether, when and with what activity treatment happens is decided in nuclear medicine according to prior findings and functional status. The question of whether a thyroid preparation becomes necessary afterwards also belongs in that supervision and not in your own hands.

Thermal ablation, the middle path

And even with a small carcinoma there is a choice

Pregnancy: a setting of its own

In pregnancy, different target values, different reference ranges and a different care framework apply. Iodine requirement is higher, TSH is kept within narrower limits, and scintigraphy is out of the question. A newly discovered nodule therefore belongs in supervised medical hands. Ultrasound and biopsy are possible in principle, and the decision is made individually. An existing thyroid medication is monitored particularly closely during this time and is never changed on your own.

And now you know why the same finding is observed in one case and clarified immediately in another.

Frequently asked questions about thyroid nodules

Where the thyroid connects to the rest of the body

A nodule does not stand on its own. It hangs on the iodine history of a region, on the metabolism, on the cofactors of energy balance and on how a person deals with an unclear finding.